Odyssey Group International (ODYY) 10-Q 4 Jun 20 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Apr. 30, 2020	Jun. 04, 2020
Document And Entity Information
Entity Registrant Name	Odyssey Group International, Inc.
Entity Central Index Key	0001626644
Document Type	10-Q
Document Period End Date	Apr. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		87,170,400
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020
Entity Small Business	true
Entity Emerging Growth	false
Entity Shell Company	false
Entity Interactive data current	Yes
Entity File Number	333-200785
Entity Incorporation State Country Code	NV

Balance Sheets (Unaudited)

Balance Sheets (Unaudited) - USD ($)	Apr. 30, 2020	Jul. 31, 2019
Current Assets:
Cash and cash equivalents	$ 26,642	$ 167,095
Prepaid expenses	143,902	302,833
Loan receivable	100,000	50,000
Total current assets	270,544	519,928
Property and equipment, net	1,103	1,517
Intangible assets, net	21,493,896	23,139,570
Total Assets	21,765,543	23,661,015
Current liabilities:
Accounts payable	64,916	47,743
Accrued wages	314,946	297,547
Contingent Liability	144,000	144,000
Notes payable, including accrued interest	1,127,551	784,913
Total liabilities	1,651,413	1,274,203
Stockholders' equity (deficiency):
Preferred stock, $.001 par value; 100,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $.001 par value; 500,000,000 shares authorized with 87,170,400 and 86,990,400 issued and outstanding	87,190	86,990
Additional paid-in capital	26,534,968	23,821,124
Deficit	(6,508,028)	(1,521,302)
Total stockholders' equity (deficiency)	20,114,130	22,386,812
Total Liabilities and stockholders' equity (deficiency)	$ 21,765,543	$ 23,661,015

Balance Sheets (Unaudited) (Par

Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Apr. 30, 2020	Jul. 31, 2019
Statement of Financial Position [Abstract]
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares Issued	87,170,400	86,990,400
Common Stock, Shares Outstanding	87,170,400	86,990,400

Statements of Operations (Unaud

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Apr. 30, 2020	Apr. 30, 2019
Income Statement [Abstract]
Revenues	$ 0	$ 0	$ 0	$ 0
Cost of goods sold	0	0	0	0
Gross profit	0	0	0	0
General and administrative expense	1,745,049	45,189	4,660,034	187,356
Loss from operations	(1,745,049)	(45,189)	(4,660,034)	(187,356)
Interest expense	(131,610)	(17,580)	(326,692)	(51,381)
Net loss	$ (1,876,659)	$ (62,769)	$ (4,986,726)	$ (238,737)
Basic net loss per share:	$ (0.02)	$ 0	$ (0.06)	$ 0
Weighted average number of shares	87,170,622	68,660,007	87,113,296	64,858,269

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficiency) (Unaudited) - USD ($)	Common stock and Paid-in-Capital	Accumulated Deficit	Total
Beginning balance, value at Jul. 31, 2018	$ 253,500	$ (1,072,877)
Common stock issued for services, value	6,000
Note payable converted to common stock	25,314
Stock issued for compensation	47,000
Net loss		(238,737)	$ (238,737)
Ending balance, value at Apr. 30, 2019	331,814	(1,311,614)	(979,800)
Beginning balance, value at Jan. 31, 2019	325,814	(1,248,845)
Common stock issued for services, value	6,000
Net loss		(62,769)	(62,769)
Ending balance, value at Apr. 30, 2019	331,814	(1,311,614)	(979,800)
Beginning balance, value at Jul. 31, 2019	23,908,113	(1,521,302)	22,386,812
Common stock issued for services, value	2,378,615
Warrants and beneficial conversion features issued in connection with convertible notes	335,430
Net loss		(4,986,726)	(4,986,726)
Ending balance, value at Apr. 30, 2020	26,622,158	(6,508,028)	20,114,130
Beginning balance, value at Jan. 31, 2020	25,493,732	(4,631,369)
Common stock issued for services, value	878,426
Warrants and beneficial conversion features issued in connection with convertible notes	250,000
Net loss		(1,876,659)	(1,876,659)
Ending balance, value at Apr. 30, 2020	$ 26,622,158	$ (6,508,028)	$ 20,114,130

Statements of Cash Flows (Unaud

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Operating activities
Net loss	$ (4,986,726)	$ (238,737)
Adjustments to reconcile net cash used in operating activities:
Depreciation and amortization expense	1,646,089	7,914
Amortization of beneficial conversion feature related to convertible notes	352,384	0
Stock based payment expense for consulting and compensation	2,378,615	47,000
Changes in operating assets and liabilities:
Decrease in other current assets	158,932	0
Increase/(decrease) in accounts payable	17,173	(14,420)
Increase in accrued wages	17,399	90,000
Increase in consulting fees charged to notes payable	0	8,750
Increase in accrued interest	75,681	51,381
Net cash used in operating activities	(340,453)	(48,112)
Financing activities
Proceeds from note payable	200,000	48,050
Net cash provided by financing activities	200,000	48,050
Net change in cash and cash equivalents	(140,453)	(62)
Cash and cash equivalents, beginning of period	167,095	390
Cash and cash equivalents, end of period	26,642	328
Noncash transactions:
Common stock issued for consulting services	0	6,000
Notes payable converted to common stock	0	25,314
Benefical conversion feature related to convertible notes	335,430	0
Note receivable related to a note payable	$ 100,000	$ 0

1. Nature of Operations

1. Nature of Operations	9 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Nature of Operations	1. Nature of Operations The corporate mission is to create or acquire distinct assets, intellectual property, and technologies with an emphasis on acquisition targets that have clinical utility and will generate positive cash flow. Our business model is to develop or acquire medical related products, engage third parties to manufacture such products and then distribute the products through various distribution channels, including third parties. The Company has assets in three different life saving technologies; the CardioMap® heart monitoring and screening device, the Save a Life choking rescue device and a unique neurosteroid drug compound intended to treat rare brain disorders. We intend to acquire other technologies and assets and plan to be a trans-disciplinary product development company involved in the discovery, development and commercialization of products and technologies that may be applied over various medical markets. We plan to license, improve and/or develop our products and identify and select distribution channels. We intend to establish agreements with distributors to get products to market quickly as well as to undertake and engage in our own direct marketing efforts. We will determine the most effective method of distribution for each unique product that we include in our portfolio. We will engage third party research and development firms who specialize in the creation of our products to assist us in the development of our own products and we will apply for trademarks and patents once we have developed proprietary products. We are not currently selling or marketing any products, as our products are in development and Food and Drug Administration ("FDA") clearance or approval to market our products will be required in order to sell in the United States.

2. Summary of Significant Accou

2. Summary of Significant Accounting Policies	9 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Use of estimates The preparation of financial statements in conformity with GAAP generally requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Basis of accounting The Company has not elected to adopt the option available under GAAP to measure any of its eligible financial instruments or other items at fair value. Accordingly, the Company measures all of its assets and liabilities on the historical cost basis of accounting unless otherwise required by GAAP. Accounts receivable Accounts receivable are carried at their estimated collectible value, net of an appropriate allowance for doubtful accounts, which is adjusted as necessary based primarily on management's evaluation of customers' past credit history and known or estimated current financial condition, the Company's relationship with the customer, current economic conditions, the historical results of, and recent trends in, the Company's collection efforts. The Company manages credit risk by evaluating the credit worthiness of significant customers prior to extending credit and thereafter. Accordingly, accounts receivable and the related allowance are evaluated periodically for collectability. Property and equipment, net Property and equipment is stated at cost less accumulated depreciation. Depreciation is recorded on a straight-line basis over the estimated useful lives of the assets. For each the nine months ended April 30, 2020, and 2019, the Company recognized depreciation expense of $414. Intangible assets, net Intangible assets (Note 4) are analyzed for potential impairment at least annually or whenever events or changes in circumstances indicate the carrying value may not be recoverable and exceeds the fair value, which is the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the intangible assets. There were no events or changes in circumstances that would indicate a possible impairment as of April 30, 2020. Beneficial Conversion Feature of convertible notes payable The Beneficial Conversion Feature ("BCF") of a convertible note (Note 5) is normally characterized as the convertible portion or feature of certain notes payable that provide a rate of conversion that is below market value or in-the-money when issued. The Company records a BCF related to the issuance of a convertible note when issued and also records the estimated fair value of any warrants issued with those convertible notes. Beneficial conversion features that are contingent upon the occurrence of a future event are recorded upon the occurrence of the event. The BCF of a convertible note is measured by allocating a portion of the note's proceeds to the warrants, if applicable, and as a reduction of the carrying amount of the convertible note equal to the intrinsic value of the conversion feature, both of which are credited to additional paid-in-capital. The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on an allocated fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Net loss per share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. No fully diluted loss per share is presented, because it would be anti-dilutive. Revenue recognition The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives, control is transferred upon shipment or upon delivery, based on the contract terms and legal requirements. Payment terms vary depending on the country of sale, type of customer, and type of product. If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money. We are not currently selling or marketing any products, as our products are in development and FDA clearance to market our products will be required in order to sell in the United States. Stock based compensation We recognize compensation expense for all restricted stock and stock option awards made to employees, directors and independent contractors. The fair value of restricted stock is measured using the grant date trading price of our stock. The fair value of stock option awards (Note 7) is estimated at the grant date using the Black-Scholes option-pricing model, and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. We have elected to recognize compensation expense for all options with graded vesting on a straight-line basis over the vesting period of the entire option. The determination of fair value using the Black-Scholes pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk free interest rate, expected dividends and projected stock option exercise behaviors. We estimate volatility based on historical volatility of our common stock, and estimate the expected term based on several criteria, including the vesting period of the grant and the term of the award. We estimate stock option exercise behavior based on assumptions regarding future exercise activity of unexercised, outstanding options. Fair Value Measurements The carrying values of cash, the note receivable, and notes payable approximate their estimated fair values because of the short-term nature of these instruments.

3. Impact of New Accounting Pro

3. Impact of New Accounting Pronouncements	9 Months Ended
	Apr. 30, 2020
Accounting Changes and Error Corrections [Abstract]
Impact of New Accounting Pronouncements	3. Impact of New Accounting Pronouncements Changes to GAAP are established by the Financial Accounting Standards Board (“FASB”), in the form of Accounting Standards Updates (“ASUs”), to the FASB’s Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. The FASB issued ASU 2017-11, Earnings Per Share The FASB issued ASU 2017-09, Compensation-Stock Compensation The FASB issued ASU 2016-02, Leases (

4. Intangible Assets - Patent

4. Intangible Assets - Patent and Distribution Rights	9 Months Ended
	Apr. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets - Patent and Distribution Rights	4. Intangible Assets – Patent and Distribution Rights FASB ASC 820, Fair Value Measurements and Disclosures Level 1 – Observable inputs, such as unadjusted quoted prices in active markets, for substantially identical assets and liabilities. Level 2 – Observable inputs other than quoted prices within Level 1 for similar assets and liabilities. These include quoted prices for similar assets and liabilities in active markets, quoted prices for identical assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. If the asset or liability has a specified or contractual term, the input must be observable for substantially the full term of the asset or liability. Level 3 – Unobservable inputs that are supported by little or no market activity, generally requiring a significant amount of judgment by management. The assets or liabilities fair value measurement level within the fair value hierarchy is based on the lowest level. The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Further, although the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. The Company purchased distribution rights to sell and distribute a new technology, CardioMap®, which is an advanced technology for early non-invasive testing for heart disease. The product distribution rights are amortized over the life of the underlying patent. The acquisition cost of $18.75 million (Level 2) is valued at the fair market value of $1.25 per share for the stock granted on the date of acquisition. For the nine months ended April 30, 2020 and 2019, the Company recognized amortization expense for distribution rights of $1,390,697 and $7,500, respectively. The Company acquired the intellectual property, know-how and patents for an anti-choking, life-saving medical device from Dr. James De Luca (“De Luca”), inventor and Murdock Capital Partners (“MCP”). The asset is valued at $675,400 (Level 2), which includes the fair market value of $1.25 per share for the stock granted on the date of acquisition, as well as stock options granted valued at $0.84 per share based upon the Black-Scholes valuation model and a onetime cash payment totaling $250,000 that will be paid upon FDA clearance of the product. The payment is recorded as a contingent liability and, based upon an independent valuation of the patents (Level 3), at April 30, 2020, the Company determined payment has a fair market value of $144,000. The intellectual property, know-how and patents are being amortized over the life of the patents. For the nine months ended April 30, 2020 and 2019, the Company recognized amortization expense of $51,005 and $0, respectively. The Company acquired the patented chemical compound for a neurosteroid as part of the joint venture agreement with Prevacus, Inc (“Prevacus”). The acquisition cost of $3.73 million (Level 2) is being amortized over the life of the patent. The asset is valued at the fair market value of $1.25 per share for the stock granted on the date of acquisition. The patents are being amortized over the life of the patents. For the nine months ended April 30, 2020 and 2019, the Company recognized amortization expense of $203,973 and $0, respectively. For the nine months ended April 30, 2020 the gross carrying amount of the intangible assets totaled $23,205,400 and accumulated amortization totaled $1,711,505 for a net amount of $21,493,895. Amortization expense recognized for the nine months ended April 30, 2020 and 2019 is $1,645,675 and $7,500, respectively. Patents are amortized over their useful lives with the weighted average years remaining of 9.74 with no residual value. Amortization is as follows over the next five years and thereafter: Quarter ending April 30, Patents Year 1 $ 2,039,003 Year 2 2,034,003 Year 3 2,029,003 Year 4 2,029,003 Year 5 2,029,003 Thereafter 11,333,882

5. Notes Payable

5. Notes Payable	9 Months Ended
	Apr. 30, 2020
Debt Disclosure [Abstract]
Notes Payable	5. Notes Payable The Company has a note payable that is subject to conversion upon an equity financing in the Company. As of April 30, 2020, the note has a balance of $803,336, which includes accrued interest totaling $223,469, and bears interest at 12.5% per annum. Because the conversion feature does not meet the criteria for characterization as a beneficial conversion feature, no portion of the proceeds from the issuance of the note was accounted for as attributable to the conversion feature. This note was amended on February 1, 2018, where the debt holder agreed to convert portions of its loan pari passu with any new investment raise of $500,000 or more. The Company issued the debt holder a common stock warrant for 4 million shares at $0.25 per share which expired on July 15, 2018. As of April 30, 2020, the Company has ten additional convertible debt notes outstanding with a balance of $324,215, which includes accrued interest totaling $20,500. The notes bear interest at 7.0% annually and the entire outstanding principal amount, together with accrued interest shall become due and payable on the date that is one (1) year from the date of issuance, unless before such date, is converted into shares of capital stock of the Company. At the option of the holder, the principal amount of the notes and any accrued interest may be converted into shares of common stock at a conversion price of $1.00 per share or at a 10% discount to the closing price on the day of conversion, but not lower than $0.80 per share. At maturity, and subject to a trickle out agreement, the Company shall have the right to either pay off the loan and any interest accrued or convert the loan amount and any interest into shares of common stock. The debt holders were issued a common stock warrant equal to 10% of the note with a price of $1.50 per share and a term for one year from the investment date. The investors are sophisticated and represented in writing that they were each an accredited investor and acquired the securities for their own account for investment purposes. The Company does not have any relationship with the investors in the notes other than the convertible notes payable. Because the conversion feature met the criteria for characterization as a beneficial conversion feature, a portion of the proceeds, including warrants, totaling $296,285, from the issuance of the notes, are accounted for as attributable to the conversion feature. The intrinsic value of convertible debt notes issued during the current quarter exceeded the proceeds in the amount of $250,000; however, the amount of the debt discount is limited to the investment. Each of the warrants and beneficial conversion features are amortized over the term (one year) from issuance.

6. Common Stock

6. Common Stock	9 Months Ended
	Apr. 30, 2020
Equity [Abstract]
Common Stock	6. Common Stock On January 9, 2019, Vivakor, Inc. (“Vivakor”) gave written notice to the Company effecting a conversion of $25,314 of convertible debt into 2,531,400 shares of Common Stock of the Company, issued to Vivakor pursuant to the Master Revolving Note, dated as of January 4, 2017, and amended as of February 1, 2018, by and between the Company and Vivakor. On April 17, 2019, the Company entered into an agreement for consulting services to be provided through April 2020. The Company granted the consultant 100,000 shares of the Company’s common stock. On May 22, 2019, the Company entered into employment agreements for two part-time employees. The Company granted the employees 10,000 shares each of the Company’s common stock. On March 22, 2019, April 17, 2019, June 1, 2019, and July 26, 2019, the Company entered into agreements for consulting services for the next 12 months. The Company granted the consultants a total of 305,000 shares of the Company’s common stock. On June 27, 2019, Odyssey entered into a Definitive Agreement with Prevacus to form a Joint Venture relating to the development of a neurosteroid for treating two orphan disorders, ALS and Niemann Picks disease. Prevacus will contribute to the JV, the chemical compound and Odyssey will be responsible for funding the JV through Phase One clinical trials. The JV company will own the patents. Each party will own the JV company equally. In addition to the JV, the two companies have entered into a share exchange agreement whereby Prevacus will receive three million shares of Odyssey common stock and Odyssey will receive one million shares of Prevacus stock. The chemical compound for the neurosteroid being developed has issued patents, and as consideration for the patented compound, Odyssey issued Prevacus two million shares of its common stock. As part of the Agreement, Dr. Jacob Vanlandingham Ph.D., CEO of Prevacus, was issued one million shares of the Company’s common stock. The Company allocated 984,000 shares to the acquisition of the patent and 16,000 shares were allocated to Dr. Vanlandingham as a Director of the Company. On June 27, 2019, Odyssey entered into a Definitive Agreement with Dr. James De Luca, inventor and Murdock Capital Partners, advisors to De Luca, to acquire the intellectual property, know-how and patents for a life-saving medical device currently in development. The Company acquired intellectual property rights, namely, United States Letters Patent No. 7,559,921, entitled “Device for Removing a Lodged Mass” which issued on July 14, 2009 and which was reissued on June 2, 2015 and received U.S. Reissue Patent No. Re 45,535 and United States Patent Number 8,454,624 also entitled “Device for Removing a Lodged Mass” which was issued on June 4, 2013. As consideration for the patent and intellectual property, the Company granted stock options totaling 600,000 shares of the Company’s stock, vesting on certain milestones. The options will be split between De Luca and MCP. The Company also granted De Luca, 20,000 common shares. A onetime cash payment totaling $250,000 will be paid to De Luca and MCP upon FDA clearance of the product. The payment is recorded as a contingent liability and, based upon an independent valuation of the patents, at April 30, 2020, the payment has a fair market value of $144,000. On December, 1, 2019, the Company entered into a corporate development, investor relations and advisory agreement. The agreement is for twelve (12) months commencing on December 1, 2019 and provides for a monthly cash fee, provided the Company has sufficient funds to pay. Fees accrue until the Company has $250,000, and then all accrued and earned compensation up to $30,000 will be paid. Upon mutual agreement, the accrued cash fee may be converted into equity at an agreed upon price per share. In addition, the Company will issue 200,000 shares of common stock, 50,000 shares vesting quarterly, beginning December 1, 2019. On February 5, 2020, the Company entered into a consulting agreement with the appointment of Mike Contarino as head of Product Development. Mr. Contarino will receive monthly payments of $2,500 and 50,000 restricted stock units vesting over time.

7. Stock Based Compensation

7. Stock Based Compensation	9 Months Ended
	Apr. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock Based Compensation	7. Stock Based Compensation We have not adopted any equity compensation plans. We have entered into an individual compensation plan for Mr. Redmond, for which Mr. Redmond has been granted stock options of 15 million shares at $0.25 per share. The options vest upon achieving the following milestones: 5 million options vest upon each milestone, when the Company obtains revenue of $5 million, $10 million and $15 million. Mr. Redmond cannot sell any of the above stock options for two years from the effective date of the employment agreement or until the Company reaches $10 million in annual revenue, whichever occurs first. The stock option vesting accelerates and becomes immediately exercisable upon the sale, merger or any transaction resulting in the majority (more than 50%) of the Company stock being obtained. The Company has not recorded any expense, as we have not determined that it is probable that the milestones will be achieved. On August 15, 2019, the Company amended its agreement with its financial consultant to included monthly payments of $5,000 and 200,000 restricted stock options to be granted in accordance with the mutual agreement of the Board’s compensation committee. As of April 30, 2020, restricted stock options have been issued and with vesting 50% vesting one year from signing On August 20, 2019, the Company entered into a consulting agreement for research and development associated with the CardioMap®. The consultant will receive monthly payments of $5,000, and 2.0 million stock options, vesting upon certain milestone achievements. As of April 30, 2020, the stock options have not been issued. On August 28, 2019, Mr. Jeff Conroy joined the Board of Odyssey as an independent director. On September 20, 2019, Mr. Jerry Casey joined the Board of Odyssey as an independent director. On October 23, 2019, Mr. John Gandolfo joined the Board of Odyssey as an independent director and has been elected chair of the audit committee. All Directors are compensated with stock in accordance with the mutual agreement of the Board’s compensation committee. As of April 30, 2020, the Company recognized $1,419,562 in board compensation expense. On January 10, 2020, the Company entered into a consulting agreement with a design group for the development of the Save A Life anti-choking device. The consultant will receive payments based on actual work performed and 50,000 stock options, vesting 50% on signing and 50% one year from signing. The stock options were valued using the Black-Scholes option pricing model with the following assumptions: expected volatility 48%, risk free interest rate 1.53%, expected life (years) 5.00

8. Income Taxes

8. Income Taxes	9 Months Ended
	Apr. 30, 2020
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes We have filed income tax returns in the U.S. federal jurisdiction and various state jurisdictions in which we operate and are currently not under examination. As of April 30, 2020, and July 31, 2019, the Company had net deferred tax assets of $2,665,449 and $260,247, respectively, consisting of net operating loss carryforwards that expire in 2035 net of an effective offsetting valuation allowance of 100%. Our effective tax rate for the nine months ended April 30, 2020 and 2019 was 0%, which differs from the statutory rate of 21% due to the valuation allowance. The Company has established the valuation allowance because due to substantial uncertainty as to the Company’s ability to continue as a going concern (Note 10), it is more likely than not at this time that the deferred tax assets will not be realized within the carryforward period.

9. Going Concern

9. Going Concern	9 Months Ended
	Apr. 30, 2020
Risks and Uncertainties [Abstract]
Going Concern	9. Going Concern We have a deficit of $6,508,028 as of April 30, 2020. For the foreseeable future, we expect to experience continuing operating losses and negative cash flows from operations as our management executes our current business plan. The cash available at April 30, 2020, of $26,642, may not provide enough working capital to meet our current operating expenses through June 4, 2021, as we continue to accrue overhead expenses. We will need to raise additional capital through a debt financing or equity offering to meet our operating and capital needs. There can be no assurance, however, that we will be successful in our fundraising efforts or that additional funds will be available on acceptable terms, if at all. Additionally, as the novel coronavirus (“COVID-19”) pandemic continues to severely impact the U.S. and global economy, our business may be impacted in a variety of ways. Political, legal or regulatory actions as a result of the COVID-19 pandemic in jurisdictions where we may plan to manufacture, source or distribute products have created supply disruptions which could affect our plans, and may cause additional supply disruptions or shortages in the future. We cannot currently predict the frequency, duration or scope of these governmental actions and supply disruptions. For example, several countries, including India and China, have increased or instituted new restrictions on the export of medical or pharmaceutical products that we distribute or use in our businesses, including key components or raw materials. Governmental authorities in many countries, including the U.S., are enacting legislative or regulatory changes to address the impact of the pandemic, which may restrict or require changes in our operations, increase our costs, or otherwise adversely affect our operations. If we are unable to raise additional capital by June 4, 2021, we will adjust our current business plan. Due to our lack of additional committed capital, recurring losses, negative cash flow, accumulated deficit, and the impact of COVID-19, there is substantial doubt about the Company’s ability to continue as a going concern.

10. Related Party Transactions

10. Related Party Transactions	9 Months Ended
	Apr. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	10. Related Party Transactions The Company has a common officer with Green Energy Alternatives, Inc. As of April 30, 2020, and 2019, Green Energy Alternatives, Inc. held 5.3 million shares of the Company’s common stock.

11. Subsequent Events

11. Subsequent Events	9 Months Ended
	Apr. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	11. Subsequent Events The Company’s management evaluates through the date of issuance of the financial statements. The Company entered into convertible promissory note agreements (“Notes”) on May 14, 2020 and May 19, 2020 with effective dates of May 5, 2020, May 6, 2020, and May 8, 2020, with accredited investors for an aggregate total of $95,000. The investors are sophisticated and represented in writing that they were each an accredited investor and acquired the securities for their own account for investment purposes. The Company does not have any relationship with the investors in the Notes other than the Notes. The Notes bear interest at 7.0% annually and are convertible, at the option of the holder or Company, into shares of common stock of the Company at one dollar ($1.00) per share or at a 10% discount to the market price on the date of conversion but in no case lower than $0.80. Unless paid or converted earlier, all of the Notes will mature on the date that is one year from their respective issuance date. Warrants equal to 10% of the shares purchased upon conversion of the Notes were issued to the holders of the Notes (the “Warrants”). The price of each Warrant is one dollar and fifty cents ($1.50) per share and the term is for one year from the investment date. On May 8, 2020, the Company received loan proceeds in the amount of $50,000 under the Paycheck Protection Program (“PPP”). The PPP, established as part of the Coronavirus Aid, Relief and Economic Security Act, provides for loans to qualifying businesses for amounts up to 2.5 times of the average monthly payroll expenses of the qualifying business. The loans and accrued interest are forgivable after eight weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The unforgiven portion of the PPP loan is payable over two years at an interest rate of 1%, with a deferral of payments for the first six months. The Company intends to use the proceeds for purposes consistent with the PPP. On May 27, 2020, the Company and Prevacus, Inc. amended the Master Agreement for a Joint Venture and Intellectual Property Purchase Agreement, dated June 26, 2019, to extend the timing of the formation of the Joint Venture to June 25, 2020.

2. Summary of Significant Acc_2

2. Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Apr. 30, 2020
Accounting Policies [Abstract]
Use of estimates	Use of estimates The preparation of financial statements in conformity with GAAP generally requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Basis of accounting	Basis of accounting The Company has not elected to adopt the option available under GAAP to measure any of its eligible financial instruments or other items at fair value. Accordingly, the Company measures all of its assets and liabilities on the historical cost basis of accounting unless otherwise required by GAAP.
Accounts receivable	Accounts receivable Accounts receivable are carried at their estimated collectible value, net of an appropriate allowance for doubtful accounts, which is adjusted as necessary based primarily on management's evaluation of customers' past credit history and known or estimated current financial condition, the Company's relationship with the customer, current economic conditions, the historical results of, and recent trends in, the Company's collection efforts. The Company manages credit risk by evaluating the credit worthiness of significant customers prior to extending credit and thereafter. Accordingly, accounts receivable and the related allowance are evaluated periodically for collectability.
Property and equipment, net	Property and equipment, net Property and equipment is stated at cost less accumulated depreciation. Depreciation is recorded on a straight-line basis over the estimated useful lives of the assets. For each the nine months ended April 30, 2020, and 2019, the Company recognized depreciation expense of $414.
Intangible assets, net	Intangible assets, net Intangible assets (Note 4) are analyzed for potential impairment at least annually or whenever events or changes in circumstances indicate the carrying value may not be recoverable and exceeds the fair value, which is the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the intangible assets. There were no events or changes in circumstances that would indicate a possible impairment as of April 30, 2020.
Beneficial Conversion Feature of convertible notes payable	Beneficial Conversion Feature of convertible notes payable The Beneficial Conversion Feature ("BCF") of a convertible note (Note 5) is normally characterized as the convertible portion or feature of certain notes payable that provide a rate of conversion that is below market value or in-the-money when issued. The Company records a BCF related to the issuance of a convertible note when issued and also records the estimated fair value of any warrants issued with those convertible notes. Beneficial conversion features that are contingent upon the occurrence of a future event are recorded upon the occurrence of the event. The BCF of a convertible note is measured by allocating a portion of the note's proceeds to the warrants, if applicable, and as a reduction of the carrying amount of the convertible note equal to the intrinsic value of the conversion feature, both of which are credited to additional paid-in-capital. The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on an allocated fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.
Net loss per share	Net loss per share Basic net loss per share is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. No fully diluted loss per share is presented, because it would be anti-dilutive.
Revenue recognition	Revenue recognition The Company recognizes revenue when control is transferred to the customer. For products sold through direct sales representatives, control is transferred upon shipment or upon delivery, based on the contract terms and legal requirements. Payment terms vary depending on the country of sale, type of customer, and type of product. If a contract contains more than one performance obligation, the transaction price is allocated to each performance obligation based on relative standalone selling price. Shipping and handling is treated as a fulfillment activity rather than a promised service, and therefore, is not considered a performance obligation. Taxes assessed by a governmental authority that are both imposed on, and concurrent with, a specific revenue producing transaction and collected by the Company from customers (for example, sales, use, value added, and some excise taxes) are not included in revenue. For contracts that have an original duration of one year or less, the Company uses the practical expedient applicable to such contracts and does not adjust the transaction price for the time value of money. We are not currently selling or marketing any products, as our products are in development and FDA clearance to market our products will be required in order to sell in the United States.
Stock based compensation	Stock based compensation We recognize compensation expense for all restricted stock and stock option awards made to employees, directors and independent contractors. The fair value of restricted stock is measured using the grant date trading price of our stock. The fair value of stock option awards (Note 7) is estimated at the grant date using the Black-Scholes option-pricing model, and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. We have elected to recognize compensation expense for all options with graded vesting on a straight-line basis over the vesting period of the entire option. The determination of fair value using the Black-Scholes pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk free interest rate, expected dividends and projected stock option exercise behaviors. We estimate volatility based on historical volatility of our common stock, and estimate the expected term based on several criteria, including the vesting period of the grant and the term of the award. We estimate stock option exercise behavior based on assumptions regarding future exercise activity of unexercised, outstanding options.
Fair Value Measurements	Fair Value Measurements The carrying values of cash, the note receivable, and notes payable approximate their estimated fair values because of the short-term nature of these instruments.

4. Intangible Assets - Paten_2

4. Intangible Assets - Patent and Distribution Rights (Tables)	9 Months Ended
	Apr. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Future Patent Amortization	Quarter ending April 30, Patents Year 1 $ 2,039,003 Year 2 2,034,003 Year 3 2,029,003 Year 4 2,029,003 Year 5 2,029,003 Thereafter 11,333,882

2. Summary of Significant Acc_3

2. Summary of Significant Accounting Policies (Details Narrative) - USD ($)	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Accounting Policies [Abstract]
Depreciation expense	$ 414	$ 414

4. Intangible Assets - Paten_3

4. Intangible Assets - Patent and Distribution Rights (Details)	Apr. 30, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Year 1	$ 2,039,003
Year 2	2,034,003
Year 3	2,029,003
Year 4	2,029,003
Year 5	2,029,003
Thereafter	$ 11,333,882

4. Intangible Assets - Paten_4

4. Intangible Assets - Patent and Distribution Rights (Details Narrative) - USD ($)	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019
Intangible asset, gross	$ 23,205,400
Accumulated amortization	1,711,505
Intangible assets, net	21,493,895
Amortization expense	$ 1,645,676	$ 7,500
Patent useful life	9 years 8 months 26 days
CardioMap [Member]
Intangible asset, gross	$ 18,750,000
Amortization expense	1,390,697	7,500
CardioMap [Member] | Fair Value Inputs Level 2 [Member]
Intangible asset fair value	18,750,000
De Luca Patents [Member]
Contingent Liability	144,000
Amortization expense	51,005	0
De Luca Patents [Member] | Fair Value Inputs Level 2 [Member]
Intangible asset fair value	675,400
Prevacus Patent [Member]
Intangible asset, gross	3,730,000
Amortization expense	203,973	$ 0
Prevacus Patent [Member] | Fair Value Inputs Level 2 [Member]
Intangible asset fair value	$ 3,730,000

5. Notes Payable (Details Narra

5. Notes Payable (Details Narrative)	9 Months Ended
	Apr. 30, 2020USD ($)$ / shares
Note Payable [Member]
Maturity date	Jan. 31, 2020
Interest rate	12.50%
Conversion price per share | $ / shares	$ 0.01
Convertible note payable outstanding	$ 803,336
Accrued interest	$ 223,469
Ten Convertible Notes [Member]
Interest rate	7.00%
Conversion price per share | $ / shares	$ 0.01
Convertible note payable outstanding	$ 324,215
Beneficial conversion feature	296,285
Accrued interest	$ 20,500

6. Common Stock (Details Narrat

6. Common Stock (Details Narrative) - USD ($)	5 Months Ended	9 Months Ended			10 Months Ended	11 Months Ended	12 Months Ended
	Jan. 09, 2019	Apr. 30, 2020	Apr. 30, 2019	Apr. 17, 2019	May 22, 2019	Jun. 27, 2019	Jul. 31, 2019
Share based compensation		$ 2,378,615	$ 47,000
Amount per share		$ 0.001					$ 0.001
Vivakor [Member]
Debt converted, amount converted	$ 25,314
Debt converted, shares issued	2,531,400
A Consultant [Member] | Consulting Services Agreement [Member]
Stock granted for compensation, shares				100,000
Two Part-Time Employees [Member] | Employment Agreements [Member]
Stock granted for compensation, shares					10,000
Consultants [Member] | Consulting Services Agreement [Member]
Stock granted for compensation, shares							305,000
Vanlandingham [Member] | Acquisition of Patent [Member]
Stock granted for acquisition of intangible assets						984,000
Vanlandingham [Member] | Director Compensation [Member]
Stock granted for compensation, shares						16,000
De Luca Agreement [Member] | Patent and Intellectual Property [Member]
Stock granted for compensation, shares						20,000
Options granted						600,000

7. Stock Based Compensation (De

7. Stock Based Compensation (Details Narrative)	9 Months Ended
	Apr. 30, 2020USD ($)$ / sharesshares
Board Compensation [Member]
Compensation expense | $	$ 1,419,562
Options [Member] | J. Michael Redmond [Member]
Options granted | shares	15,000,000
Fair value options granted per share | $ / shares	$ 0.25

8. Income Taxes (Details Narrat

8. Income Taxes (Details Narrative) - USD ($)	9 Months Ended
	Apr. 30, 2020	Apr. 30, 2019	Jul. 31, 2019
Income Tax Disclosure [Abstract]
Net deferred tax assets	$ 2,665,449		$ 260,247
Net operating loss carryforwards expiration date	Dec. 31, 2035
Effective tax rate	21.00%	21.00%

9. Going Concern (Details Narra

9. Going Concern (Details Narrative) - USD ($)	Apr. 30, 2020	Jul. 31, 2019	Apr. 30, 2019	Jul. 31, 2018
Risks and Uncertainties [Abstract]
Operating deficit	$ (6,508,028)	$ (1,521,302)
Cash and cash equivalents	$ 26,642	$ 167,095	$ 328	$ 390

10. Related Party Transactions

10. Related Party Transactions (Details Narrative) - shares	Apr. 30, 2020	Jul. 31, 2019	Apr. 30, 2019
Common stock owned	87,170,400	86,990,400
Green Energy Alternatives [Member]
Common stock owned	5,300,000		5,300,000